Compare Medtronic PLC (MDT) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Rocket Lab USA Inc — how do they compare? Medtronic PLC trades at $88.02 (market cap $112.24B), while Rocket Lab USA Inc trades at $67.5 (market cap $43.74B). The key difference: Medtronic PLC is far larger — about 2.6× Rocket Lab USA Inc's market cap, and Medtronic PLC pays a 3.28% dividend while Rocket Lab USA Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Rocket Lab USA Inc for 29 Days on average.
| MDT | RKLB | |
|---|---|---|
Market Cap | $112.24B | $43.74B |
Volume | 105,663,236 | 22,892,581 |
Sector | Health | Industrials |
52-Week High | $105.35 | $150.23 |
52-Week Low | $73.75 | $39.48 |
Typical Hold Time | 63 Days | 29 Days |
Enterprise Value | $131.58B | $41.57B |
Dividend Yield | 3.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $87.80, up 2.68% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a 13.93% net income margin and consistent dividend growth over 49 years. Revenue growth accelerated to $33.54B in 2025, and analyst consensus targets $97.80, implying 11% upside. Recent news highlights regulatory approvals for medical devices and a $4B MiniMed exchange offer.
MDT offers value with a 3.2% dividend yield and reasonable valuation (P/E 21.6), but faces headwinds from technical bearishness and rising debt. The stock's appeal hinges on execution of growth initiatives in cardiovascular and neuroscience segments, though competitive and macroeconomic risks persist.
Rocket Lab (RKLB) trades at $67.47, down 6.19% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of -$198.21M in 2025, though revenue grew to $601.80M. Recent news highlights a record 20-launch deal with Synspective, expanding the backlog past 100 missions, providing a positive catalyst amid ongoing losses and high valuation multiples.
The outlook remains speculative; strong analyst consensus (76% buy ratings) and a $107 price target suggest long-term growth potential from launch demand, but profitability challenges, cash burn, and competitive pressure from SpaceX pose significant risks. Investment hinges on execution toward Neutron rocket commercialization and path to sustained profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
